<<  Back

Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants For Measuring Continuous Blood Glucose

Jun 20,2018
PhysioTel™ Digital M0G and M1G: Designed to Improve Animal Welfare in Large Animal Models

ST. PAUL, Minn. and HOLLISTON, Mass., June 20, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic monitoring, launched two telemetry implants, the PhysioTel™ Digital M0G and M1G, to meet the changing needs of diabetes researchers.

The M0G and M1G implants revolutionize methods for measuring and evaluating blood glucose levels in large animals.  Historically, researchers have taken intermittent blood samples, providing an incomplete profile, yet adding a great deal of labor and animal stress.  The new implants allow researchers to collect second-by-second blood glucose levels, temperature and activity from conscious, freely moving large animals —providing stress-free data collection while enhancing animal welfare.  They are compatible with social housing environments and feature an automated configuration to minimize human error, while providing fast study start-up.

“It’s exciting to introduce transformational technologies,” said Jeffrey Duchemin, President and CEO of Harvard Bioscience. “We anticipate these devices will change the way diabetes and other metabolic research will be performed.”

Diabetes is an escalating global problem. Specifically in the United States, it is the seventh leading cause of death and affects approximately 30 million people. Significant investment is made in research of the disease each year as treatment options are limited, and a cure has yet to be found. In 2017, the National Institutes of Health awarded approximately $1.105 billion for diabetes research, and many private organizations award millions of dollars every year. Kaiser Associates named diabetes the third highest indication in their annual report on pharmaceutical research and development spending.

About Data Sciences International

Data Sciences International (DSI) provides a complete preclinical platform to assess physiological data for research ranging from basic, to drug discovery, and drug development. DSI is the leading provider of telemetry systems, pulmonary solutions, associated software platforms, and services. DSI is a subsidiary of Harvard Bioscience (Nasdaq:HBIO) a global developer, manufacturer, and marketer of a broad range of specialized products for life science research. For more information, please visit our website at www.datasci.com.

About Harvard Bioscience

Harvard Bioscience is a global developer, manufacturer and marketer of a broad range of solutions to advance life science. Our products are sold to thousands of researchers in over 100 countries through our global sales organization, websites, catalogs, and through distributors including Thermo Fisher Scientific Inc., VWR, GE Healthcare, and other specialized distributors. We have sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden, Spain, France, Canada and China. For more information, please visit our website at www.harvardbioscience.com.

Contact:
Harvard Bioscience
Corey Manchester
Vice President, Corporate Controller
Tel: 508 893 8999

Primary Logo

Source: Harvard Bioscience, Inc.